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Abstract
Introduction: In Namibia, the Cockcroft-Gault (C-G) method is recommended for monitoring renal function in HIV
patients receiving Tenofovir Disoproxil Fumarate (TDF)-containing Combination Antiretroviral Therapy (cART).
However, there are concerns with the potential over-reporting of TDF-associated renal impairment.
Methods: Retrospective study comparing the renal function of patients receiving 2nd line cART with either C-G or
Chronic Kidney Disease-Epidemiology (CKD-EPI) methods.
Results: 71 patients were included. The majority (62%) received TDF-containing 1st line ART. All received 2nd-
line cART containing TDF/Lamivudine (3TC)/Zidovudine (AZT) and LPV/r. Before switching to 2nd-line cART, 40.8%
and 8.5% had abnormal eGFR according to C-G and CKD-EPI methods respectively. During 2nd-line cART, 47.9%
and 7% of patients had abnormal eGFR by C-G and CKD-EPI methods, respectively, and 4.1% and 2.8%
respectively experienced a decline in eGFR. There was a significant lack of agreement between the two methods.
Conclusion: The C-G method has the potential to report more cases of TDF-associated renal impairment.
Consequently, national guidelines in Namibia and other pertinent countries should be reviewed if this is the
recommended method for monitoring renal function.
Keywords: Tenofovir; Renal function; eGFR; Cockcroft-Gault;
Chronic kidney disease; Epidemiology; Namibia
Background
Antiretroviral (ARV) medicines typically undergo fast-track
approval due to the recognised need to improve the quality-of-life and
prolong the lives of people infected with the Human Immuno-
Deficiency Virus (HIV) [1,2]. Sub-Saharan Africa, being the most
affected region of the world with the HIV pandemic, has gained
tangible benefits from the use of combination antiretroviral therapy
(cART) [3-5]. Despite these tangible benefits, ARV medicines are
associated with adverse drug reactions, the impact, incidence, and
prevalence of which is not completely measured at the time these
medicines are approved for clinical use especially if patients have
greater co-morbidities than those enrolled into Phase III trials [6].
Nevertheless, the establishment of pharmacovigilance centres like the
Therapeutics Information and Pharmacovigilance Centre (TIPC) in
Namibia exposes the safety concerns pertaining to these ARV
medicines. This is important in Africa given the appreciable genetic
differences between patients in Africa and the western countries where
many studies are currently undertaken [7,8].
Earlier in 2016, we published a paper on the ‘effect of changing from
first-to second-line cART on renal function’ [9] studying the effects at a
leading health facility in Namibia, from which all patients who were
receiving second-line cART (n=71) were included in this study. We
used the Cockcroft-Gault (C-G) formula to estimate CrCl [10],
because at the time of the study the C-G method was the
recommended method in Namibia for assessing renal function in all
patients receiving Tenofovir Disoproxil Fumarate (TDF)-containing
cART in Namibia [9,11]. TDF is a pro-drug for Tenofovir (TFV) the
active ingredient [9], which is known to cause renal impairment by, but
not limited to, interfering with the proximal tubular function [12,13].
As such, in Namibia, any TDF dosage adjustments or withdrawals were
generally prompted by the estimated CrCl via the C-G formula.
In regards to the monitoring of renal function, the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) method, which
approximates to the Gold-Standard, is known to be better than the C-
G method [14]. However as mentioned, the C-G method is the one
currently recommended for monitoring renal function in Namibia
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[9,11]. However, we do not know the extent to which the C-G method
could affect the number of reports of TDF-associated renal
impairment. Furthermore, we do not know the effect of the result of
renal function assessed by the C-G method can have on subsequent
clinical decisions such as a reduction in the dose of TDF or withdrawal
of TDF.
Awareness of the superiority of the CKD-EPI method over the C-G
method [14] prompted us to use the patients in our earlier study to
firstly assess the relationship between the C-G and the CKD-EPI eGFR
results. Secondly, ascertain the extent of any differences between the C-
G and CKD-EPI methods in the proportion of patients considered to
have experienced renal impairment. Lastly, we set out to discover if
there was a difference between the C-G and CKD-EPI eGFR results in
the number and/or proportion of potential clinical decisions on TDF’s
dose or TDF’s withdrawal.
As a result, guide the authorities in Namibia on whether to continue
with recommending the C-G method or change to the CKD-EPI
method. This may also have implications for other African resource
limited countries if the C-G formula is also being recommended for
monitoring renal function in patients who are infected with the HIV
and are receiving a cART regimen containing TDF.
Objectives
The first objective of this study was to assess if there was agreement
between the eGFR results computed by the C-G and CKD-EPI
methods in our study population. The second objective was to identify
eGFR results by either the C-G and CKD-EPI methods that met the
definition of decline in renal function as per the criteria used in this
study,   which was also previously used by  Kalemeera et al. [9]. These
 would
qualify to be reported as TDF-associated renal impairment to the
pharmacovigilance centre. The
reduction or withdrawal of TDF.
Methods
This was retrospective study assessing the potential effects that the
C-G method may have on ADR reports and clinical decisions
pertaining to TDF, and comparing these with the CKD-EPI method.
This was based on patients receiving second-line cART in out-patients
at the Katutura Intermediate Hospital [9]. In the previous study, the C-
G method was used to calculate CrCl, which in this study was
converted to eGFR using the patients’ body surface area (The C-G
equation that was used is documented in Box 1).
Dichotomous Grouping of renal function
Any eGFR below 90 ml/min/1.73 m was categorised as abnormal. eGFR was
calculated using the C-G and CKD-EPI formulae. For C-G the formula was:
[(140–Age) X Weight]/SeCr (X0.85 for females), while for CKD-EPI the general
formula was:C X [(SeCr/0.7)e] X [(0.993) Age ], where C varied according to
ethnicity, and e varied according to the SeCr measurements and sex.
Further categorisation of renal function
The eGFR was further categorised into stages I to IV, where stage I was ≥ 90;
stage II was 60–<90; stage III was 30–<60; and stage IV was <30, ml/min/1.73
m2.
Declined renal function
Renal function was considered to have declined if the last eGFR during second-
line cART was ≥ 25% less than the eGFR computed during first-line cART. In
addition, when the SeCr was noted to have increased by ≥ 25%, during second-
line cART, renal function was considered to have declined.
Improved renal function
Renal function was considered to have improved if the last eGFR during
second-line cART was ≥ 25% more than the eGFR during first-line cART. When
the SeCr was noted to have decreased by ≥ 25%, during second-line cART, the
renal function was considered to have improved, even though the change in
eGFR was <25%
Box 1: Definitions of renal function.
We also computed another set of eGFR values using the CKD-EPI
method (The CKD-EPI equations that were used are documented in
Box 1). The computations of eGFR were based on the last recorded
SeCr measurements before patients were switched to second-line cART
and the last SeCr measurements during second-line cART. We used the
criteria documented in Table 1 to place the patients in the requisite
category of renal function. We used the criteria documented in Box 1
to determine if the patient had experienced a decline or improvement
in renal function.
To assess the relationship between eGFR values computed by C-G
and CKD-EPI methods, we used Cohen’s Kappa; Pearson correlation;
linear-regression coefficients; and Bland-Altman plots. We used Odds
Ratios, Pearson Chi-Square test, Fisher’s Exact Test, and Binomial
Distribution to assess the difference between the eGFR values
computed by C-G and CKD-EPI methods on the potential numbers of
reports of TDF-associated renal impairment adverse reactions. Lastly,
to assess the potential effect of the eGFR computed by the C-G method
on TDF’s dose or withdrawal in comparison with the eGFR computed
by the CKD-EPI method, we used Odds Ratio. We set the confidence
level at 95%, and statistical significance at a p-value <0.05.
Test type SeCr
(mg/dL)
Equations for estimating renal
function
Cockcroft-Gault [(140–Age) X Weight]/SeCr
CKD-EPI(Black female)
≤ 0.7 166 X [(SeCr/0.7)-0.329] X [(0.993)Age]
>0.7 166 X [(SeCr/0.7)-1.209] X [(0.993)Age]
CKD-EPI (Black male)
≤ 0.9 163 X [(SeCr/0.7)-0.411] X [(0.993)Age]
>0.9 163 X [(SeCr/0.7)-1.209] X [(0.993)Age]
CKD-EPI (mixed race -
females)
≤ 0.7 144 X [(SeCr/0.7)-1.209] X [(0.993)Age]
>0.7 144 X [(SeCr/0.7)-1.209] X [(0.993)Age]
Table 1: Formulas for evaluating renal function.
Results
Patient characteristics
A total of 71 patients were included in this study. Of these 57.7%
(n=41) were female. Table 2 contains details of the mean weight and
age before and during second-line cART. 62% (n=44) of the patients
received TDF/lamivudine (3TC) and EFV or NVP, and one patient
received TDF/FTC/EFV. All patients were receiving a second-line
regimen that consisted of TDF/Lamivudine (3TC)/Zidovudine (AZT)
and LPV/r. Upon evidence of treatment failure, patients were switched
to second-line cART. At the time of data collection, these patients had
spent an average of 5.2 ± 2.7 years on first-line cART, and an average of
1.8 ± 0.5 years on second-line cART (Table 2).
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and CKD-EPI methods in the proportions of patients 
requiring dosage
 third objective was to compare 
the C-G
 Result
Demographics
Number of Patients (%) 71 (100)
Average weight, Kg (before 2nd line cART) 62.4 ± 12
Average weight, Kg (during 2nd line ART, at data collection) 64 ± 12
Average Age before switch (years) 42 ± 6.8
Average age at data collection (years) 44 ± 7.1
ART Data
First-line ART statistics
No. of patients, received AZT-based first line cART 16 (22.5%)
No. of patients, received D4T-based first line cART 11 (15.5%)
No of patients, received TDF-based first line cART 44 (62.0%)
Second-line ART statistics
Number receiving TDF/3TC/AZT and LPV/r 71 (100%)
Reasons for switching to second-line ART
Immunological failure 69 (97.2%)
Virological failure 35 (49.3%)
Clinical failure 3 (4.2%)
Period on ART regimen
Mean (SD) period (years) spent on first-line cART 5.2 ± 2.7
Mean (SD) period (years) spent on second-line cART 1.8 ± 0.5
SD: Standard Deviation.
Table 2: Patient Characteristics.
Renal function before second-line therapy
Before switching to second-line ART, the C-G and CKD-EPI
methods showed that 40.8% (n=29) and 8.5% of the patients
respectively had abnormal renal function (Table 3). During second line
cART, the C-G method indicated that more patients (n=10, 14.1%)
experienced a decline in renal function, than shown by the CKD-EPI
method (n=2, 2.8%). Similarly, the number of patients who
experienced an increase in eGFR according to the C-G method (n=6)
was slightly lower than those who experienced the same according to
the CKD-EPI method (n=8). Moreover, the eGFR calculations during
second-line cART yielded similar results to those we observed to have
occurred during first-line cART (Table 3).
Methods
CKD-EPI: Number (%) of patients per stage
During first-line cART During second-line cART
Stage I Stage II StageIII Stage I Stage II StageIII
C-G: Number (%) of patients per
stage
Stage I 42 (59.2) - - 37† (52.1) - -
Stage II 23 (32.4) 5 (7.0) - 28# (39.5) 2#ß (2.8) -
Stage III - 1 (1.4) - 2# (2.8) 1#ß (1.4) 1#ß (1.4)
Total 65 (91.6) 6 (8.4) - 67 (94.4) 3 (4.2) 1 (1.4)
†Includes 6 cases of improved eGFR; #Includes 10 cases of declines in eGFR; ‡Includes 5 new cases of improved eGFR; and ßIncludes one further decline, and 3 new
cases of decline in eGFR
Table 3: Number (Percentage) of patients in different stages of renal function as categorised by using the C-G- or the CKD-EPI formulae, before
second-line cART.
Assessment of agreement between C-G and CKD-EPI
findings
Based on Cohen’s kappa, the results show a lack of agreement
between C-G and CKD-EPI eGFR computations during first-line
cART (kappa=0.224, p=0.003) and during second-line cART
(kappa=0.110, p=0.042) (Table 3). Pearson correlation analysis showed
that the eGFR for the two methods had a strong relationship (r=0.803;
p=0.000) during first-line cART, and there were similar findings during
second-line cART (r=0.749; p=0.000), (Figure 1: Panel A and Panel B).
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Figure 1: Correlation scatter plot for C-G and CKD-EPI
measurements of renal function.
The correlation scatter plots (Figure 1) show that the eGFR
measured by C-G and CKD-EPI correlated strongly. However, the
Bland-Altman plots based on the mean bias (standard deviation)
during first-line cART: 17.4 (11.4), and during second-line cART: 21.9
(15.6), exposed the absence of agreement between the two tests (Figure
2: Panel C and Panel D). Linear regression analysis confirmed the lack
of agreement between the two methods: beta-coefficient of -0.191
(p=0.001), and -0.336 (p=0.001).
Figure 2: The Bland-Altman Plots comparing the C-G and CKD-
EPI methods on measuring renal function.
Difference between C-G and CKD-EPI
Potential numbers of TDF-associated renal impairment reports
We computed the difference in eGFR between the last measurement
during first-line cART and the last measurement during second-line
cART, for both C-G and CKD-EPI. We reviewed the magnitude of the
difference in eGFR and determined which result met the criteria for
decline in renal function. Our findings were that the chance of
identifying TDF-associated ADRs with C-G was five times as much as
using the CKD-EPI methodology. This finding was significant with the
Odds Ratio (Cl 95%; OR=5 (1.06–23.6); p-value=0.04), and also with
other tests (Table 4).
C-G
(Number of
reports)
CKD-EPI
(Number of
report)
Odds Ratio
(Confidence Interval)
P-Values
Odds
Ratio
Pearson Chi-
Square
Fisher’s
Exact Test
Binomial
Distribution
Assessment of Potential
ADRs 10 2 5.0 (1.06–23.6) 0.04 .001 0.027 0.002
Assessment of Potential
changes in TDF’s dose/
withdrawl
1 0 3.0 (0.12–74.9) 0.5 - - -
Table 4: Numbers and analyses of TDF associated renal impairment and TDF dose reduction/withdrawal.
Potential numbers of TDF dose reductions or withdrawals
We assessed each patient’s record of eGFR computed by CG and
CKD-EPI to determine if the computed eGFR had the potential to
recommend a dosage reduction in TDF or its withdrawal. We found
that the chance of reducing TDF’s dose or withdrawing TDF when C-
G is used was three times that of the CKD-EPI methodology (Cl 95%;
OR=3.0 (0.12–74.9); p-value=0.05). Since the CKD-EPI results had no
patient with an eGFR requiring TDF’s dosage reduction, the p-value
was only computable for the Odds Ratio (Table 4).
Discussion
Michel et al. and Willems et al. compared the eGFR computed by C-
G, CKD-EPI, and Modification of Diet in Renal Disease (MDRD) with
the gold-standard. They found that the CKD-EPI and MDRD methods
out-performed the C-G method. The C-G method was associated with
lower eGFR computations. The authors also found that the CKD-EPI
eGFR closely approximated the gold-standard [15,16]. In their study,
Matsushita et al. found that CKD-EPI, which out-performs MDRD, led
to the reclassification of many patients from lower to higher renal
function categories [17]. Since our study was retrospective, and the
gold standard is generally not used in clinical practice in Namibia, and
because CKD-EPI out-performs MDRD, which out-performs the C-G
method [17,18], we compared the C-G based estimations of GFR with
those computed by the CKD-EPI method. Since the superiority of
CKD-EPI over C-G is an established fact, we did not implement this
study to affirm or disprove the CKD-EPI’s superiority. However, we set
out  to highlight the potential impact the  lesser method,  is the C-G
method, may have on the number of reports of TDF-associated renal
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impairment in Namibia, and its potential to affect clinical decisions
such as TDF’s dose reduction or its withdrawal in patients purportedly
experiencing renal impairment.
As expected, the C-G method yielded lesser eGFR values than the
CKD-EPI method. According to Pearson Correlation analysis, the
eGFR results computed by C-G and CKD-EPI had a strong positive
correlation. However, according to the Bland-Altman plots (Figure 2)
and linear regression analyses, the eGFR results of C-G and CKD-EPI
were not close to agreeing. Since the CKD-EPI based method is
reflective of the true renal function of the patient, the related eGFR
results showed that only a few patients experienced a decline in renal
function, contrary to the C-G based estimations, which suggested
more patients were experiencing renal impairment. Our findings are
similar to Botev et al. study in which the C-G method wrongfully
categorised 60% of the study patients into lower renal function
categories [19].
Our findings show that the C-G method has implications on TDF’s
safety because this method yielded a greater proportion of patients
with lower stages of renal function before and after switching (Table 3).
Furthermore, the C-G method detected more events of decline in renal
function (14.0%, n=10) than the CKD-EPI method (2.8%, n=2).
Interestingly, our findings indicate that the C-G method has not had
implications on TDF’s use to any extent different from the CKD-EPI
method. This is based on the fact that the majority of patients who
were declared to have experienced a decline in renal function via the
C-G method had an eGFR that was above 50 ml/min, below which
dosage adjustments are required [20]. Furthermore, if we assume that
eGFR had stabilised at the estimated levels, the C-G based method
ceases to pose any challenges of wrongfully categorising patients into
lower renal function stages. However, the latter could not be
confirmed. In regards to TDF’s withdrawal or dosage-interval
adjustments due to low eGFR computations, our results show no
significant difference between CKD-EPI and C-G (OR=3; p=0.05).
However, since the C-G method underestimates eGFR, a significant
proportion of patients are likely to miss-out on its use. (NB: The
Namibia cART guidelines recommend that before initiating TDF-
based first-line cART, the CrCl should be calculated. They also state
that initiation of TDF-containing cART should be avoided in cART
naïve patients with CrCls below 60 ml/min). Despite the absence of
significance in regards to switching or dose reduction in the study
patients, there remains a concern that the use of the C-G method may
place patients experiencing actual declines of their renal function in
categories of lower renal function status, as observed by Botev et al.
[19]. Pharmacovigilance centres need to be aware of this fact especially
in countries where the C-G method is still used for assessing renal
function.
Through the passive reports received by the Therapeutics
Information and Pharmacovigilance Centre (TIPC) in Namibia, some
work by TIPC has been published [21-23]. Amongst these adverse
reaction reports, are reports of renal impairment associated with TDF
[21], which were based on reduced CrCl computed by the C-G
method. Since the C-G method is likely to raise false alarms of renal
impairment, it is likely that some of the reports of TDF-associated
renal impairment were not reflective of the actual renal function of the
patient. These findings may also be true for other African countries.
Consequently, the use of C-G method to assess renal function in
patients receiving TDF-containing cART is likely to wrongfully
increase the number of reports of TDF-associated renal impairment.
Subsequently, the health system’s concern for cardiovascular disease in
these patients may be escalated. Additionally, the low eGFR computed
by the C-G method can influence clinical decisions such as
prolongation of TDF’s dosage intervals. As a result, subjecting the
patients to sub-optimal concentrations of TDF (and 3TC) thereby
creating an environment for the emergence of resistance against cART
regimens. Lastly, the low eGFR computed by the C-G method can
result in TDF’s withdrawal.
The addition of the Urine-Dipstick to CrCl as strategy to detect
TDF-associated renal impairment is a recent development in cART
guidelines [24,25]. The use of the urine dipstick in this regard is based
on the fact that the normal nephron would reabsorb all the filtered
glucose except in hyperglycaemic patients, who at the detection of
glycosuria have plasma glucose levels above the normal threshold for
glucose reabsorption: 180 mg/dl [26]. Consequently, the cART
guidelines rest on the understanding of the pathophysiology of TDF-
associated proximal tubulopathy, during which the reabsorption of
glucose is likely interrupted resulting in glycosuria in euglycaemic
patients [13,27]. The addition of the urine dipstick is promising to
partly or fully negate the possible mis-categorisation of renal
impairment by the C-G method in patients receiving TDF-containing
cART. This is because the low eGFR in the presence of proximal
tubulopathy likely co-occurs with glycosuria and albuminuria.
However, we have not found any literature to date that discusses the
co-variance of eGFR and urine-glucose or urine-proteins in patients
receiving TDF-containing cART. In addition, the sensitivity of the
urine dipstick in this patient category needs to be evaluated. This
should be the subject of future research. In any event, there are
concerns with the C-G method in Namibia and other countries
[28,29].
Limitations
The major limitation to our study is that there was no gold standard
to compare the C-G- and CKD-EPI-eGFR computations with. It may
be that C-G-based assessments identified actual renal impairment
cases. We are also aware that we only assessed 71 patients. This is
because we built on a previous study conducted in Namibia to address
current concerns with the C-G method. However, in view of the
findings, we believe our study results are valid, providing guidance to
key stakeholder groups in Namibia and throughout Africa. We will be
following this up in future studies.
Conclusion
The C-G method is likely to increase the number of reports of renal
impairment compared with the CKD-EPI method. The increased
incidence in renal impairment reports is of concern to the
pharmacovigilance centre, whose critical role is to safe-guard the
population against drug related adverse reactions. The
disproportionate increase in TDF-associated renal impairment can
instigate policy changes in its use. Our study has also shown that the
wrong eGFR computations by the C-G method may not influence
clinical decisions at the individual patient level, at least not within 2.6
years of second-line cART. It is apparent that within 2.6 years of
second line cART, the C-G method did not lead to any clinical decision
pertaining to TDF’s use such as prolongation of TDF’s dosage interval
in patients with normal renal function and the withdrawal of TDF
from the cART regimen from such patients. The repercussions of such
decisions would include the emergence of resistance, new infections
with a resistant virus, the replacement of TDF with zidovudine-a less
safe ARV medicine than TDF, and lastly increased expenditure on
Citation: Kalemeera F, Cockeran M, Mubita M, Kibuule D, Naikaku E, et al. (2017) The Potential Effect of Using the Cockcroft-Gault Method on
Tenofovir-Associated Renal Impairment Reports and on Clinical Decisions Regarding Tenofovir Use in Individual Patients: Implications
for the Future. J Infect Dis Preve Med 5: 170. doi:10.4172/2329-8731.1000170
Page 5 of 6
J Infect Dis Preve Med, an open access journal
ISSN:2329-8731
Volume 5 • Issue 3 • 1000170
second-line cART. However, these were not observed. The results of the
Urine Dipstick may prove to be beneficial in terms of confirmatory
renal function tests. However, the evidence of this is currently lacking.
Since TDF-associated nephropathy can be progressive, it is advisable
that better methods of renal function assessment than the C-G
method, such as the CKD-EPI method, should be considered alongside
the use of urine-dipsticks, as this may prevent administration of low
doses of TDF instigated by falsely low GFR estimates computed by the
C-G method. These are implications for the future in Namibia.
Key Message
The strong positive correlation between eGFR values by C-G and
CKD-EPI methods does not necessarily mean that the clinical
interpretations of renal function from both tests are the same. It is
known that the C-G based method is associated with lower eGFR
values than the Gold-Standard, unlike the CKD-EPI method.
In regards to pharmacovigilance, the C-G method of assessment of
renal function in patients receiving TDF-containing cART is likely to
increase the number of reports of TDF-associated renal impairment,
which is not a true reflection of actual renal function. The addition of
the urine dipstick may or may not be beneficial in identification of
clinical tubulopathy, and thus needs to be evaluated.
When the C-G method is used to assess renal function, the result of
reduced eGFR may lead to dose adjustment of TDF, subjecting the
patient to sub-therapeutic levels and consequently to the emergence of
resistance against TDF.
There is need to utilise better methods to assess renal function in
patients receiving TDF-containing cART, such as CKD-EPI as this
method more closely reflects the Gold-Standard results.
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